Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Studies have shown that dose-dense chemotherapy reduces the risk of recurrence and death of
breast cancer patients comparing with standard-schedule chemotherapy. But some research data
indicate that HR+/HER2- breast cancer patients benefit from dose-dense chemotherapy while
some have negative results. How to identify HR+/HER2 breast cancer patients who are more
likely to benefit from dose-dense chemotherapy is strongly necessary. Ki67 is a marker
reflecting the proliferation of tumor cells. Breast cancer patients with high Ki67 are more
likely to benefit from dose-dense chemotherapy. The purpose of this project is to investigate
the efficacy and safety of neoadjuvant dose-dense chemotherapy for HR+/HER2- breast cancer
patients with high proliferation index. At the same time, we will explore biomarkers, such as
MammaPrint and BluePrint, to further identify patients who benefit more from neoadjuvant
dose-dense chemotherapy.